Mondobiotech Holding AG Company presentation
Mondobiotech Holding AG Company presentation
Mondobiotech Holding AG Company presentation
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Licensed Products<br />
• Aviptadil platform to Lung Rx LLC, wholly owned subsidiary of United Therapeutics Corp. –<br />
UTHR (from Biogen Idec Inc.)<br />
Indication: Pulmonary Arterial Hypertension (PAH)<br />
Milestones: US$ 10m end of phase III; US$ 20m marketing authorization<br />
Royalties: approx. 10% on net sales on the whole platform<br />
Status: Clinical POC/Phase IIa<br />
Indications: respectively Sarcoidosis, Idiopathic Interstitial Pneumonia (IIP-IPF) and Acute Respiratory<br />
Distress Syndrome/Acute Lung Injury (ARDS/ALI)<br />
Milestones: US$ 10m end of phase III; US$ 10m marketing authorization<br />
Royalties: approx. 10% on net sales on the whole platform<br />
Status: Clinical POC<br />
Biogen Idec in-licensed the IP rights on the platform in 2006. In February 2010, with the agreement of Biogen Idec, the<br />
platform was licensed to Lung Rx, with Biogen Idec remaining financially involved for the PAH indication. Both companies<br />
focused on the development of Aviptadil only for the disease which was their major interest, i.e. PAH. In May 2011, Lung<br />
Rx for strategic reasons returned to mondoBIOTECH and all IP rights, know-how and ownership of data of the Aviptadil<br />
Platform. The data of the double- blind multinational Phase II study performed on PAH suggested that Aviptadil may be<br />
promisingly re-directed for already identified acute indications and delivered to patients via a more suitable formulation<br />
and route of administration. Based on such data and on internal know-how on Aviptadil, we intend to start Phase II<br />
development for Aviptadil in ARDS/ALI together with our Community.<br />
53
Change language